2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024
Open accessThe DOI matches its Crossref record; 240 of the 240 references it cites were found in a registry or an index; 152 of the 254 sources its claims cite were checked for support.
Abstract
The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
CoChat Summary
TL;DR
This ADA Standards of Care chapter provides updated recommendations for diagnosing and classifying diabetes, prediabetes, and related forms, including diagnostic thresholds, screening intervals, and classification categories. It emphasizes confirmatory testing, A1C limitations, risk-based screening, and special populations such as type 1 diabetes, gestational diabetes mellitus (GDM), cystic fibrosis–related diabetes (CFRD), posttransplantation diabetes mellitus (PTDM), pancreatic diabetes, and monogenic diabetes.
Key findings
- Diabetes diagnostic criteria: A1C ≥6.5% (≥48 mmol/mol), FPG ≥126 mg/dL (≥7.0 mmol/L), 2-h PG ≥200 mg/dL (≥11.1 mmol/L) during 75-g OGTT, or random plasma glucose ≥200 mg/dL (≥11.1 mmol/L) with classic hyperglycemic symptoms/crisis; absent unequivocal hyperglycemia, diagnosis requires two abnormal results. Prediabetes is defined by A1C 5.7–6.4% (39–47 mmol/mol), FPG 100–125 mg/dL (5.6–6.9 mmol/L; IFG), or 2-h PG 140–199 mg/dL (7.8–11.0 mmol/L; IGT).
- Classification includes type 1 diabetes (5–10% of diabetes), type 2 diabetes (90–95%), specific types due to other causes, and GDM. Misdiagnosis is common and can occur in ~40% of adults with new type 1 diabetes; type 1 diabetes staging shows ~44% 5-year risk of symptomatic disease at stage 1 and ~60% risk by 2 years and ~75% within 5 years at stage 2.
- Screening: begin at age 35 years for all adults; consider earlier in adults with overweight/obesity plus one or more risk factors; repeat at minimum 3-year intervals if normal. In children/adolescents, consider risk-based screening after puberty or age 10 years, whichever is earlier, with overweight/obesity plus risk factors.
- Special populations: GDM screening at 24–28 weeks; one-step IADPSG criteria increase GDM diagnosis (e.g., 11.5% vs 4.9% in a 2021 USPSTF review) without demonstrated improved health outcomes. CFRD occurs in about 20% of adolescents and 40–50% of adults with cystic fibrosis; annual OGTT screening begins by age 10, and A1C is not recommended for screening due to low sensitivity. PTDM diagnosis is best made once stable on immunosuppression, usually at least 45 days after transplantation, with OGTT preferred. Monogenic diabetes accounts for <5% of diabetes; 80–85% of neonatal diabetes cases have a monogenic cause, and 30–50% of KATP-related neonatal diabetes improves with high-dose oral sulfonylureas.
Methods
- Design: ADA Standards of Care clinical practice guideline/consensus recommendations, updated annually by the ADA Professional Practice Committee, an interprofessional expert committee.
- Data/sample: No primary study sample; the chapter synthesizes published evidence and expert consensus. It references an ADA evidence-grading system (A/B/C/E) detailed in the Introduction and Methodology.
- Main analysis: Narrative synthesis of diagnostic, classification, and screening evidence with graded recommendations; no meta-analysis or primary data collection is reported in this chapter.
Limitations
- Stated evidence gaps include insufficient evidence for continuous glucose monitoring (CGM) for screening/diagnosis of prediabetes or diabetes; unknown optimal screening interval; uncertain benefit of treating early abnormal glucose metabolism; lack of randomized controlled trials for treating versus not treating GDM diagnosed by IADPSG but not Carpenter-Coustan criteria; and limited data on how treating maternal hyperglycemia affects offspring metabolic outcomes.
- Stated classification/diagnostic limitations include common misdiagnosis (e.g., ~40% of adults with new type 1 diabetes), poorly understood type 2 diabetes genetics, inadequate genetic data in diverse populations, and A1C unreliability in conditions such as hemoglobin variants, pregnancy, glucose-6-phosphate dehydrogenase deficiency, HIV, hemodialysis, recent blood loss/transfusion, or erythropoietin therapy.
- Evident from the text: this is a consensus guideline rather than a primary systematic review or meta-analysis; recommendations are graded A/B/C/E, with some based on expert consensus (E), and many cited studies are observational/cohort rather than randomized trials.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 2.1 Flowchart for investigation of suspected type 1 diabetes in newly diagnosed adults, based on data from White European populations. 1 No single clinical feature con fi rms type 1 diabetes in isolation. 2 Glutamic acid decarboxylase (GAD) should be the primary antibody measured and, if negative, should be followed by islet tyrosine phosphatase 2 (IA-2) and/or zinc transporter 8 (ZnT8) where these tests are available. In individuals who have not been treated with insulin, antibodies against insulin may also be useful. In those diagnosed at < 35 years of age who have no clinical features of type 2 diabetes or monogenic diabetes, a negative result does not change the diagnosis of type 1 diabetes, since 5 -10% of people with type 1 diabetes do not have antibodies. 3 Monogenic diabetes is suggested by the presence of one or more of the following features: A1C < 58 mmol/mol ( < 7.5%) at diagnosis, one parent with diabetes, features of a speci fi c monogenic cause (e.g., renal cysts, partial lipodystrophy, maternally inherited deafness, and severe insulin resistance in the absence of obesity), and monogenic diabetes prediction model probability > 5% (diabetesgenes.org/exeter-diabetes-app/ModyCalculator). 4 A C-peptide test is only indicated in people receiving insulin treatment. A random sample (with concurrent glucose) within 5 h of eating can replace a formal C-peptide stimulation test in the context of classi fi cation. If the result is $ 600 pmol/L ( $ 1.8 ng/mL), the circumstances of testing do not matter. If the result is < 600 pmol/L ( < 1.8 ng/mL) and the concurrent glucose is < 4 mmol/L ( < 70 mg/dL) or the person may have been fasting, consider repeating the test. Results showing very low levels (e.g., < 80 pmol/L [ < 0.24 ng/mL]) do not need to be repeated. Where a person is insulin treated, C-peptide must be measured prior to insulin discontinuation to exclude severe insulin de fi ciency. Do not test C-peptide within 2 weeks of a hyperglycemic emergency. 5 Features of type 2 diabetes include increased BMI ( $ 25 kg/m 2 ), absence of weight loss, absence of ketoacidosis, and less marked hyperglycemia. Less discriminatory features include non-White ethnicity, family history, longer duration and milder severity of symptoms prior to presentation, features of the metabolic syndrome, and absence of a family history of autoimmunity. 6 If genetic testing does not con fi rm monogenic diabetes, the classi fi cation is unclear and a clinical decision should be made about treatment. 7 Type 2 diabetes should be strongly considered in older individuals. In some cases, investigation for pancreatic or other types of diabetes may be appropriate. 8 A person with possible type 1 diabetes who is not treated with insulin will require careful monitoring and education so that insulin can be rapidly initiated in the event of glycemic deterioration. 9 C-peptide values 200 -600 pmol/L (0.6 -1.8 ng/mL) are usually consistent with type 1 diabetes or maturity-onset diabetes of the young but may occur in insulin-treated type 2 diabetes, particularly in people with normal or low BMI or after long duration. Reprinted and adapted from Holt et al. (36).](https://figures.cochat.ai/paper-figures/7be96ed282694b1c85997763e16ae474/2-diagnosis-and-classification-of-diabetes-i-standards-of-care-in-diabetes2024-i-figure-1.png)

Verification
Claims the paper makes
99 Valid · 9 Not valid · 35 Not checked · 32 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“However , in 2003 the ADA adopted the new range of 100 -125 mg/dL (5.6 -6.9 mmol/L) to better de fi ne IFG so that the population risk of developing diabetes with IFG would be similar to that with IGT (11).”
What the sources say
- Disputedcites [11] Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, 2003, Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, Diabetes Care sourceExperimental — accuracy not yet measured
In “The new criteria” (p. 8), the committee defines IFG as fasting plasma glucose of 110 to <126 mg/dL, not 100–125 mg/dL. The paper describes both IFG and IGT as risk factors for future diabetes, but it does not say the lower IFG threshold was adopted to make their population risks similar. (LLM, conf=0.91)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“In most cases, such stressor steroidinduced hyperglycemia resolves by the time of discharge (142,143).”
What the sources say
- Partly supportedcites [142] Thomas, 2000, Early peri-operative hyperglycaemia and renal allograft rejection in patients without diabetes, BMC Nephrol sourceExperimental — accuracy not yet measured
The Results (Hyperglycaemia; page unavailable) show that mean glucose fell from immediately after surgery to the morning of day 2. The Discussion (page unavailable) describes steroid exposure and postoperative hyperglycaemia, but the paper does not report whether most patients’ hyperglycaemia resolved by discharge. (LLM, conf=0.82)
- Disputedcites [143] Chakkera, 2009, Hyperglycemia during the immediate period after kidney transplantation, Clin J Am Soc Nephrol sourceExperimental — accuracy not yet measured
The Abstract (Results) says hyperglycemia was sustained throughout hospitalization and that 66% of patients without pretransplantation diabetes required insulin at discharge. The Discussion says the authors did not know what proportion would ultimately recover, rather than finding that most cases resolved by discharge. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Because periodontal disease is associated with diabetes, the utility of screening in a dental setting and referral to primary care as a means to improve the diagnosis of prediabetes and diabetes has been explored (108 -110)”
What the sources say
- Not checked — no full text of the sourcecites [108] Lalla, 2013, Dental findings and identification of undiagnosed hyperglycemia, J Dent Res source
- Not checked — no full text of the sourcecites [109] Lalla, 2011, Identification of unrecognized diabetes and pre-diabetes in a dental setting, J Dent Res source
- Supportedcites [110] Herman, 2015, Screening for prediabetes and type 2 diabetes in dental offices, J Public Health Dent source
The Discussion (page unavailable) describes periodontal disease and its sequelae as risk factors for dysglycemia, supporting the general association claimed. The paper’s own Results (page unavailable) found no association between clinical evidence of periodontitis and dysglycemia in its study sample, so it should not be cited as demonstrating that association in this cohort. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In a community-based study of African American and non-Hispanic White adults without diabetes, baseline A1C was a stronger predictor of subsequent diabetes and cardiovascular events than fasting glucose (82).”
What the sources say
- Partly supportedcites [82] Selvin, 2010, Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults, N Engl J Med sourceExperimental — accuracy not yet measured
The Abstract Conclusions state that glycated hemoglobin was more strongly associated than fasting glucose with cardiovascular disease risk, but only similarly associated with diabetes risk. The study population was community-based and included Black and White adults without diabetes. Page numbers are not provided in our copy. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“The epidemiologic studies that formed the basis for recommending A1C to diagnose diabetes included only adult populations (112).”
What the sources say
- Could not verifycites [112] Cowie, 2010, Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988-2006, Diabetes Care sourceExperimental — accuracy not yet measured
The introductory discussion (page unavailable) says an international expert committee recommended A1C for diagnosis, but does not give the ages of participants in the epidemiologic studies behind that recommendation. The Research Design and Methods section (page unavailable) includes participants aged 12 and older in this paper’s own analysis; that does not establish the ages in the studies the committee relied on. Searches for adult-only evidence and pediatric populations did not resolve the claim. (LLM, conf=0.73)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
74 more claims · 46 with their cited sources checked
Create a free account to see all 175 claims and to verify the 3 references still open.
- Probably not a substantial claim. 29
- It may state two separate claims as one. 75
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“HbA1c can be affected by some non-glycaemic factors, including anaemia due to iron deficiency or malaria, specific haemoglobin variants (eg, HbS and HbF), other haemoglobinopathies, polycythaemia due to living in high altitude, liver and kidney diseases, HIV, and specific drugs such as antiretroviral therapy for HIV.”
From Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants (2024) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many clinical guidelines recommend using a second confirmatory test for diabetes diagnosis and initiating treatment,6,21–23 although there is variation in this guidance.”
From Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants (2024) · cites this paper as [21]
Experimental — accuracy not yet measured
Citations
Cites
Items 201–240 of 240
Early pregnancy hemoglobin A1C and pregnancy outcomes: a population-based study
Chen, L., Pocobelli, G., Yu, O., Shortreed, S. M., Osmundson, S. S., Fuller, S., Wartko, P. D., Mcculloch, D., Warwick, S., Newton, K. M., et al. (2019) · American Journal of Perinatology · doi:10.1055/s-0038-1675619 · Cited by 36
Awa, W. L., Schober, E., Wiegand, S., Herwig, J., Meissner, T., Schmidt, F., Molz, E., & Holl, R. W. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.09.011 · Cited by 35
Putman, M. S., Norris, A. W., Hull, R. L., Rickels, M. R., Sussel, L., Blackman, S. M., Chan, C. L., Ode, K. L., Daley, T., Stecenko, A. A., et al. (2023) · Diabetes Care · doi:10.2337/dc23-0380 · Cited by 35
Lawrence, J. M., Slezak, J. M., Quesenberry, C., Li, X., Yu, L., Rewers, M., Alexander, J. G., Takhar, H. S., Sridhar, S., Albright, A., et al. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108624 · Cited by 34
Carbohydrate Intake Prior to Oral Glucose Tolerance Testing
Klein, K. R., Walker, C. P., McFerren, A. L., Huffman, H., Frohlich, F., & Buse, J. B. (2021) · Journal of the Endocrine Society · doi:10.1210/jendso/bvab049 · Cited by 32
Autoimmune polyendocrine syndrome induced by immune checkpoint inhibitors: A systematic review
Zhao, Z., Wang, X., Bao, X.-Q., Ning, J., Shang, M., & Zhang, D. (2021) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-020-02699-1 · Cited by 30
Economic evaluations of gestational diabetes mellitus screening: a systematic review
Mo, X., Gai Tobe, R., Takahashi, Y., Arata, N., Liabsuetrakul, T., Nakayama, T., & Mori, R. (2021) · Journal of Epidemiology · doi:10.2188/jea.je20190338 · Cited by 29
Diabetes remission and relapse after bariatric surgery: a nationwide population-based study
Conte, C., Lapeyre-Mestre, M., Hanaire, H., & Ritz, P. (2020) · Obesity Surgery · doi:10.1007/s11695-020-04924-3 · Cited by 29
Humphreys, A., Bravis, V., Kaur, A., Walkey, H. C., Godsland, I. F., Misra, S., Johnston, D. G., & Oliver, N. S. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107789 · Cited by 28
Accuracy of a point-of-care hemoglobin A1c assay
Nathan, D. M., Griffin, A., Perez, F. M., Basque, E., Do, L., & Steiner, B. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819836101 · Cited by 26
Franck Thompson, E., Watson, D., Benoit, C. M., Landvik, S., & McNamara, J. (2020) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.07.010 · Cited by 26
Zhu, Y., Qian, L., Liu, Q., Zou, J., Zhou, Y., Yang, T., Huang, G., Zhou, Z., & Liu, Y. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2019.0007 · Cited by 26
A Clinical Guide to Monogenic Diabetes
Carmody, D., Støy, J., Greeley, S. A. W., Bell, G. I., & Philipson, L. H. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800892-8.00002-6 · Cited by 25
Hyperglycemia management in patients with posttransplantation diabetes
Galindo, R. J., Fried, M., Breen, T., & Tamler, R. (2016) · Endocrine Practice · doi:10.4158/ep151039.ra · Cited by 25
Management of post-transplant diabetes mellitus: an opportunity for novel therapeutics
Montero, N., Oliveras, L., Soler, M. J., & Cruzado, J. M. (2021) · Clinical Kidney Journal · doi:10.1093/ckj/sfab131 · Cited by 25
The association between glycemic control and clinical outcomes after kidney transplantation
Ramirez, S. C., Maaske, J., Kim, Y., Neagu, V., DeLange, S., Mazhari, A., Gao, W., Emanuele, M. A., Emanuele, N., Baldwin, D., et al. (2014) · Endocrine Practice · doi:10.4158/ep13463.or · Cited by 24
GCK-MODY in the US Monogenic Diabetes Registry: description of 27 unpublished variants
Sanyoura, M., Letourneau, L., Knight Johnson, A. E., del Gaudio, D., Greeley, S. A. W., Philipson, L. H., & Naylor, R. N. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.04.017 · Cited by 23
Putman, M. S., Norris, A. W., Hull, R. L., Rickels, M. R., Sussel, L., Blackman, S. M., Chan, C. L., Ode, K. L., Daley, T. C., Stecenko, A. A., et al. (2023) · Diabetes · doi:10.2337/db22-0949 · Cited by 22
Yefet, E., Jeda, E., Tzur, A., & Nachum, Z. (2020) · Journal of Diabetes · doi:10.1111/1753-0407.12985 · Cited by 21
Mansi, I. A., Sumithran, P., & Kinaan, M. (2023) · BMJ · doi:10.1136/bmj-2022-071727 · Cited by 20
Boudreau, V., Reynaud, Q., Bonhoure, A., Durieu, I., & RABASA-LHORET, R. P. R. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2018.11.005 · Cited by 20
Cheng, C.-Y., Chen, C.-H., Wu, M.-F., Wu, M.-J., Chen, J.-P., Liu, Y.-M., Hou, Y.-C., & Wang, H.-Y. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17124581 · Cited by 18
Kim, H. D., Chang, J.-Y., Chung, B. H., Kim, C.-D., Lee, S.-H., Kim, Y. H., & Yang, C. W. (2021) · Annals of Transplantation · doi:10.12659/aot.927984 · Cited by 17
Boe, B., Barbour, L. A., Allshouse, A. A., & Heyborne, K. D. (2019) · American Journal of Obstetrics & Gynecology MFM · doi:10.1016/j.ajogmf.2019.02.003 · Cited by 16
Bardenheier, B. H., Wu, W.-C., Zullo, A. R., Gravenstein, S., & Gregg, E. W. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108726 · Cited by 16
Reproducibility of a prediabetes classification in a contemporary population
Chadha, C., Pittas, A. G., Lary, C. W., Knowler, W. C., Chatterjee, R., Phillips, L. S., Aroda, V. R., Lewis, M. R., Pratley, R., Staten, M. A., et al. (2020) · Metabolism Open · doi:10.1016/j.metop.2020.100031 · Cited by 15
Gulsoy Kirnap, N., Bozkus, Y., & Haberal, M. (2020) · Experimental and Clinical Transplantation · doi:10.6002/ect.tond-tdtd2019.o8 · Cited by 14
Pham Vu, T., Nguyen Thi Thuy, D., Truong Quy, K., Nguyen Thi Thu, H., Nguyen Van, D., Diem Thi, V., Do Manh, H., Nguyen Trung, K., Do, Q., Tran Viet, T., et al. (2021) · Transplant Immunology · doi:10.1016/j.trim.2021.101392 · Cited by 13
Post-transplantation diabetes mellitus in pediatric patients
Grundman, J. B., Wolfsdorf, J. I., & Marks, B. E. (2020) · Hormone Research in Paediatrics · doi:10.1159/000514988 · Cited by 12
Use of hemoglobin A1c to identify dysglycemia in cystic fibrosis
Darukhanavala, A., Van Dessel, F., Ho, J., Hansen, M., Kremer, T., & Alfego, D. (2021) · PLoS ONE · doi:10.1371/journal.pone.0250036 · Cited by 12
Smith, C. J., Almodallal, Y., & Jatoi, A. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01089-9 · Cited by 11
Dental clinic: potential source of high-risk screening for prediabetes and type 2 diabetes
Jadhav, A., Tarte, P., & Puri, S. (2019) · Indian Journal of Dental Research · doi:10.4103/ijdr.ijdr_80_18 · Cited by 10
Gilmour, J. A. (2019) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2019.02.002 · Cited by 9
Pillay, J., Donovan, L., Guitard, S., Zakher, B., Korownyk, C. S., Gates, M., Gates, A., Vandermeer, B., Bougatsos, C., Chou, R., et al. (2021) · Cited by 9
Immune Checkpoint Inhibitors and Risk of Type 1 Diabetes
Chen, X., Affinati, A. H., Lee, Y., et al. (2022) · doi:10.2337/figshare.19165250 · Cited by 3
A Pragmatic, Randomized Clinical Trial of Gestational Diabetes Screening
Hillier, T. A., Pedula, K. L., Ogasawara, K. K., et al. (2021) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000771056.71675.a2 · Cited by 3
1360-P: Increase in Diabetic Ketoacidosis at Diagnosis of T1D in Colorado Children, 2010-2017
Alonso, G. T., Coakley, A., Pyle, L., Manseau, K., Thomas, S., Rewers, M., & Rewers, A. (2019) · Diabetes · doi:10.2337/db19-1360-p
Treatment of Gestational Diabetes Mellitus Diagnosed Early in Pregnancy
Simmons, D., Immanuel, J., Hague, W. M., et al. (2023) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000996800.58164.4b
Cost and Cost-Effectiveness of Large Scale Screening for Type 1 Diabetes in Colorado
McQueen, R. B., Geno, C., Waugh, K., Frohnert, B. I., Steck, A. K., Yu, L., Baxter, J., & Rewers, M. (2020) · doi:10.2337/figshare.12076692.v1
Research works printed but not linked: 1
- International Diabetes Federation . IDF Diabetes Atlas, 10th edition. Brussels, Belgium, International Diabetes Federation, 2021. Accessed 26 September 2023. Available from https://www.diabetesatlas.org/atlas/tenth-edition/
Cited by
Martin, S. S., Aday, A. W., Allen, N. B., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Bansal, N., Beaton, A. Z., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001303 · Cited by 1,080
Zhou, B., Rayner, A. W., Gregg, E. W., Sheffer, K. E., Carrillo-Larco, R. M., Bennett, J. E., Shaw, J. E., Paciorek, C. J., Singleton, R. K., Barradas Pires, A., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)02317-1 · Cited by 1,013
Raverdy, V., Tavaglione, F., Chatelain, E., Lassailly, G., De Vincentis, A., Vespasiani-Gentilucci, U., Qadri, S. F., Caiazzo, R., Verkindt, H., Saponaro, C., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03283-1 · Cited by 169
“…status was defined at baseline on the basis of a previous history of diabetes, use of antidiabetic medications, fasting plasma glucose ≥126 mg dl −1 (7.0 mmol l −1 ) and/or 2 h plasma glucose ≥200 mg dl −1 (11.1 mmol l −1 ) during oral glucose tolerance test, and/or HbA1c ≥6.5% (48 mmol l −1 ) 41 .”
InfluentialHou, X.-Z., Lv, Y., Li, Y., Wu, Q., Lv, Q., Yang, Y.-T., Li, L., Ye, X., Yang, C.-Y., Wang, M.-S., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02173-7 · Cited by 170
Haller, M. J., Bell, K. J., Besser, R. E. J., Casteels, K., Couper, J. J., Craig, M. E., Elding Larsson, H., Jacobsen, L., Lange, K., Oron, T., et al. (2024) · Hormone Research in Paediatrics · doi:10.1159/000543035 · Cited by 151
“Notably, the 2024 ADA Standards of care include HbA1c of 5.7 – 6.4% (39 – 47 mmol/mol) or ≥ 10% increase in HbA1c as diagnostic of Stage 2 T1D [87].”
Influential
Metadata
- Authors
- American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., Khunti, K., Lingvay, I., Matfin, G., McCoy, R. G., Perry, M. L., Pilla, S. J., Polsky, S., Prahalad, P., Pratley, R. E., Segal, A. R., Seley, J. J., Selvin, E., Stanton, R. C., & Gabbay, R. A.
- ORCID
- ElSayed, Nuha A.
- Aleppo, Grazia
- Bannuru, Raveendhara R.
- Bruemmer, Dennis
- Collins, Billy S.
- Ekhlaspour, Laya
- Gaglia, Jason L.
- Hilliard, Marisa E.
- Johnson, Eric L.
- Khunti, Kamlesh
- Lingvay, Ildiko
- McCoy, Rozalina G.
- Perry, Mary Lou
- Pilla, Scott J.
- Polsky, Sarit
- Prahalad, Priya
- Pratley, Richard E.
- Segal, Alissa R.
- Seley, Jane Jeffrie
- Selvin, Elizabeth
- Stanton, Robert C.
- Gabbay, Robert A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2023-12-11
- Volume
- 47
- Issue
- Supplement_1
- Pages
- S20-S42
- ISSN
- 0149-5992 (ISSN-L)
- PMC
- PMC10725812
- OpenAlex
- W4389560718
- Cited by
- 2,086
- References
- 232
- Citations by year
- 2026: 771 · 2025: 903 · 2024: 408 · 2023: 1
- FWCI
- 74.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (K23DK121942)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- diabetes diagnosis, diabetes classification, diabetes mellitus, clinical guidelines, American Diabetes Association standards of care, quality of care
- MeSH terms
- Diabetes Mellitus, Endocrinology, Humans, Reference Standards, Societies, Medical, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.